ctx320 - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,821 +0.57%

DJIA 48,229 +0.67%

Nasdaq 25,023 +0.52%

DAX 23,852 -0.47%

Gold $4,196 +0.16%

Oil $98.45 +1.82%

BTC $71,887 +0.73%

VIX 20.68 -14.82%

EUR/USD 1.1785 -0.02%

ETH $2,207 -0.06%

S&P 500 6,821 +0.57%

DJIA 48,229 +0.67%

Nasdaq 25,023 +0.52%

DAX 23,852 -0.47%

Gold $4,196 +0.16%

Oil $98.45 +1.82%

BTC $71,887 +0.73%

VIX 20.68 -14.82%

EUR/USD 1.1785 -0.02%

ETH $2,207 -0.06%

ctx320

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor in Chief Conclusion In summary,…